Randomized trial shows reduced risks of CKD progression and cardiovascular events in patients with type 2 diabetes, suggesting finerenone's potential benefits.
In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).
No takes yet. Share an insight, caveat, or question.
Bakris et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: